Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial.
- DOI
- 10.1111/1346-8138.17834
- Published
- 2025-07-17
- Container
- J Dermatol
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/1346-8138.17834,
title = {Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial.},
author = {Zhang J and Ding Y and Wang P and Li L and Pan W and Lu Y and Cheng H and Jiang X and Ho JC and Guo S and Seo SJ and Gold LS and Blauvelt A and Zhuo J and Zhong Y and Becker B and Liu L and Banerjee S and Thaçi D.},
year = {2025},
journal = {J Dermatol},
doi = {10.1111/1346-8138.17834},
url = {https://doi.org/10.1111/1346-8138.17834}
}RIS
TY - JOUR TI - Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial. AU - Zhang J AU - Ding Y AU - Wang P AU - Li L AU - Pan W AU - Lu Y AU - Cheng H AU - Jiang X AU - Ho JC AU - Guo S AU - Seo SJ AU - Gold LS AU - Blauvelt A AU - Zhuo J AU - Zhong Y AU - Becker B AU - Liu L AU - Banerjee S AU - Thaçi D. PY - 2025 JO - J Dermatol DO - 10.1111/1346-8138.17834 UR - https://doi.org/10.1111/1346-8138.17834 ER -
APA
J, Z., Y, D., P, W., L, L., W, P., Y, L., H, C., X, J., JC, H., S, G., SJ, S., LS, G., A, B., J, Z., Y, Z., B, B., L, L., S, B., & D., T. (2025). Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial.. J Dermatol. https://doi.org/10.1111/1346-8138.17834
Source records
- europe-pmc · retrieved 2026-09-27T03:42:27.570Z